Managing ART Options in the Setting of HIV Drug Resistance
You must Login or Create Account in order to register for this event
Presenter
Moderator
February 17, 2026
11:00 AM - 12:15 PM PTOverview
Assessment of Needs
Although the overall incidence of HIV drug resistance has declined in the era of modern antiretroviral therapy (ART), some individuals continue to experience treatment failure due to the emergence of drug resistance. These patients require innovative and effective therapeutic strategies to achieve and maintain viral suppression. This webinar will review current treatment options for individuals with drug-resistant HIV, explore advances in drug resistance testing, and highlight approaches that support improved adherence and sustained virologic control.
Learning Objectives
On completion of this activity, learners will be able to:
- Describe what is currently known about the management of resistance to existing drugs, including new and long-acting medications
- Identify and apply up-to-date options for HIV resistance and diagnostic testing
- Describe the role of archived DNA proviral HIV-1 genotype testing to guide adjustments in ART regimens
- Implement strategies to simplify ART regimens to enhance adherence and virologic outcomes
Registration
Who Should Attend
This webinar is designed for clinical decision makers who are actively involved in HIV care and research, including physicians, physician assistants, nursing professionals, pharmacists, and other health care professionals.
Individual registration is required in order to receive CME credit or a certificate of participation.
Registration closes on Tuesday, February 17, 2026, 11:30 AM (PT).
For more information or questions, please contact the registration department at registration@iasusa.org or 415-544-9400.
Conflicts of Interest
In the interest of maintaining the independence of its continuing medical education (CME) activities, the International Antiviral Society–USA (IAS–USA) requires all persons with control of educational content (eg, faculty, Scientific Leadership Board, Governance Board, and program planner) to disclose any financial relationships with ineligible companies (previously defined as “commercial interests”) that they have had within the past 24 months. Any real or apparent conflicts of interest of those parties are resolved and mitigated prior to the CME activity being delivered. Individuals who refuse to disclose financial interests may not participate in IAS–USA CME activities.
The Accreditation Council for Continuing Medical Education (ACCME) defines ineligible companies as “those whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.”
IAS–USA will identify and resolve ahead of time any possible conflicts of interest that may influence CME activities with regard to exposition or conclusion. Information about financial relationships with ineligible companies for the presenter and planners/reviewers is below and in the slides prior to the presentation of educational content.
Presenter
Dr Sax reported receiving consulting or advisor fees from Shionogi & Co, Ltd. (Updated September 30, 2025)
Moderator
Dr Klein reported consulting for, and grants paid to her institution from, ViiV Healthcare, AbbVie, and Gilead Sciences, Inc. (Updated August 8, 2025)
Planner/Reviewer
Planner/Reviewer 1 reported no relevant financial relationships with ineligible companies (Updated November 12, 2025)
Planner/Reviewer 2 reported no relevant financial relationships with ineligible companies (Updated November 12, 2025)
COW Board
The financial relationships of the COW Board can be found here: https://www.iasusa.org/activities/cases-on-the-web/about-cows/cow-webinars-editorial-board/
CME Credits
The International Antiviral Society–USA (IAS–USA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The IAS–USA designates this live activity for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
ABIM MOC Points
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.25 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. IAS-USA, the CME activity provider, will submit your participant information (eg, name, date of birth, activity credits earned, ABIM MOC number) to ABIM through the PARS system for the purpose of reporting ABIM MOC credits.
Nursing Credits
This activity is eligible for ANCC credit, see final CNE activity announcement for specific details.
Pharmacy Credits
This activity is eligible for ACPE credit, see final CPE activity announcement for specific details.
Grant Support
IAS–USA funding comes from a variety of sources. The largest single source of revenue is CME participant registration fees. Other funding sources include grants from ineligible companies (previously defined as “commercial interests”) and diagnostics industries, private donations, and gifts-in-kind from local community businesses and individuals. Support from ineligible companies will be announced as it becomes available.
Frequently Asked Questions
View our list of FAQs about attending a webinar.
Further Questions?
Please contact the registration department at registration@iasusa.org or 415-544-9400.